Get started

ATOS

Long | ATOS | This is a rare opportunityNASDAQ:ATOS 1- It's at support level right now, consolidated for 2 weeks. 2- It had a direct offering of 50m$ 2 weeks ago, new Institutional investors joined the team, they already had public offering and they didn't need any cash, they have cash for 3-4 years of operational cost. 3- it has 2 products for waiting P2 approval, one if them halted in Feb, because the results were great but didn't published the official approval from FDA yet, (Expected in 2 weeks) 4- it has a cure for cancer, put money in this company is a good cause and RIO is insane, 5- Average of price target is 6.25$, it means 300% . 6- buy-out is one of the possible options, and I expect an average price of 11$, it should be happen before shareholder meeting (less than 2 month) * these are my ideas and could be wrong 100%, but if it be right thanks me later. lol
NASDAQ:ATOSLong
by shkspr
1
ATOS - Triple Bottom with a Breakout?Set up looks great. Triple bottom, break out and retest of a diagonal resistance. I absolutely dislike stocks like this but I like the chart. Will there be a catalyst to move this? The only catalyst for this one is the recent FDA "safe to proceed" letter to continue ovarian cancer treatment. If it actually materializes, could see a run towards levels above. It will only move if it catches momo crowd, otherwise just another garbage stonk.
NASDAQ:ATOSLong
by bossmodetrader
Long | ATOSNASDAQ:ATOS Updated chart pattern on ATOS: the bullish pennant changed to Symmetric Triangle, By nature of this pattern, it has potential to go up or down, but when we study other variables and recent price actions I expect a break-out not break-down, price target for symmetric triangle is equal to the distance from the high and low of the earliest part of the pattern applied to the breakout price point. For example, for ATOS low of $2.45 and move up to $3.80 before the price range narrows over time. A breakout from $2.45 would imply a price target of ~$4.30, or $3.80 – $2.45 = $1.35, then + $3 = $4.35. it's exactly fit to the Fibonacci level 1, $4.33. I put mental SL around 2.80, to reduce my shares and buy cheaper, if to goes down, it goes to 2$
NASDAQ:ATOS
by shkspr
9
SMALLCAP - FUNDAMENTAL & TECHNICAL - ATOS Long to 15Price Action: - Contrarian investing and whale hunting lead me to this stock... when I see high effort to short, I see opportunity. Usually when institutions find a stock they want, they will attack with naked shorting and FUD to drive the price down and shake out retail. - 4% inst. owned, +330% inst. transactions, confirming my suspicions. - 70M Float, this one will be hard to keep down. - Take a look at the huge accumulating since March. Somebody knows something is up. Fundamentals: "The AT-301 formulation was designed to work like a mucosal vaccine, blocking entry of the virus into the cells to begin with and thus, hopefully, preventing a COVID-19 infection" "AT-301 is being developed with a nasal spray delivery mechanism because many COVID-19 patients are infected via the nasal passage. Collectively, the components of AT-301 are believed to help maintain a protective mucosal like layer within the nasal cavity with both anti-viral properties and protective mucosal like barrier that may lead to lower infectivity and reduced symptoms in COVID-19 patients due to their interference with the spike protein of the virus in the nasal cavity and upper respiratory tract. Atossa’s nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains (RBD) via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier." "The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups. Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A. Part B is a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days." - Potential breakthroughs in cancer and COVID research... Pharma is taking off, this company WILL be pumped Could be the next big one.. I won't be sleeping on this opportunity.
NASDAQ:ATOSLong
by UnknownUnicorn1043646
2